Momentous sprint at the 2156 Olympics?

By Andrew J. Tatem, Carlos A. Guerra, Peter M. Atkinson, Simon I. Hay. Nature, 2004

784 citations recorded by the source corpus.

The 2004 Olympic women's 100-metre sprint champion, Yuliya Nesterenko, is assured of fame and fortune. But we show here that — if current trends continue — it is the winner of the event in the 2156 Olympics whose name will be etched in sporting history forever, because this may be the first occasion on which the race is won in a faster time than the men's event.

Subfields: Genetics, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/4b76c0c031d48183a4f3a3a4494cb84413445675

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Carlos L. Arteaga
2. C. Der
3. J. Engelman
4. P. Roberts

In Pulmonary and Respiratory Medicine

1. Carlos L. Arteaga
2. Adi F. Gazdar
3. N. Hynes
4. C. Der
5. J. Engelman
6. P. Roberts

Citations in the corpus

• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer (2007, background): “, EGFR and HER2) can cause hyperactivation of Ras leading to upregulated MAPK signaling (Lynch et al., 2004; Stephens et al., 2004; Hynes and Lane, 2005).”
• Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers (2006, background): “Recently, somatic mutations of HER2 TK domain were also reported in lung adenocarcinomas.(20,30) Of interest, HER2 mutations were of the same type and targeted the same region (30 of the aC-helix) in exon 20 as did EGFR in-frame duplications/insertions(20) (Figs.”
• Cancer genomics: from discovery science to personalized medicine (2011, background): “and intragenic mutations in ERBB2 in non-small-cell lung cancer (NSCLC”
• The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis (2007, background): “Somatic mutations within the HER2 kinase domain have been described in a small subset of lung cancers, predominantly in Asian populations, and very rarely in gastric, colorectal and breast cancers (Figure 1, region D) (Stephens et al., 2004; Shigematsu et al., 2005; Lee et al., 2006).”
• Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. (2005, background): “Recently, mutations of HER2 were reported in lung adenocarcinomas and offer the potential of additional therapy targeted at the altered protein (22).”